Cancer Diagnosis Market Report 2025 (Global Edition)

Global Cancer Diagnosis Market Report 2024 Market Size Split by Type Outlook: (Consumables, Instruments), by Application Outlook: (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Other Cancer...

Cancer Diagnosis Market Report Description

We have various report editions of Cancer Diagnosis Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Cancer Diagnosis Market Insights Video

Competitive Landscape of the Cancer Diagnosis Market

The development of cancer diagnostics that can detect cancer in its early stages will be essential for all companies operating in this industry. Globally, cancer diagnostics providers are estimated to place a high priority on research to maximize their business opportunities and stay competitive. In order to boost sales of cancer diagnostics, it will also be advised that all market participants take use of supportive government programs and awareness efforts in the future.

In November 2023, Abbott's HPV test, intended for use with the Alinity m platform, received FDA approval. This test detects high-risk HPV strains linked to cancer and permits primary screening for the virus. Abbott's cervical cancer prevention and diagnosis services are improved by the approval. (Source:https://abbott.mediaroom.com/2023-11-02-Abbott-Receives-FDA-Approval-for-HPV-Test-to-Run-on-Alinity-m,-Offering-Primary-HPV-Screening-and-Assessment-of-High-Risk-Cancer-Causing-Types-of-HPV) In April 2023, Quest Diagnostics acquired Haystack Oncology in an all-cash deal to expand its MRD diagnostic offerings. The first focus was on lung, breast, and colorectal cancers, with the intention of enhancing patient outcomes through the early detection of MRD following treatment. (Source:https://newsroom.questdiagnostics.com/2023-04-27-Quest-Diagnostics-to-Acquire-Haystack-Oncology,-Adding-Sensitive-Liquid-Biopsy-Technology-for-Improving-Personalized-Cancer-Care-to-Oncology-Portfolio) In June 2022, Roche introduced the new BenchMark ULTRA PLUS cancer testing technology, which allows for prompt, individualized patient care. (Source:https://diagnostics.roche.com/global/en/news-listing/2022/roche-launches-new-benchmark-ultra-plus-system-for-cancer-diagno.html#:~:text=Basel%2C%2029%20June%202022%20%2D%20Roche,regarding%20a%20patient's%20care%20journey.)

Top Companies Market Share in Cancer Diagnosis Industry: (In no particular order of Rank)

• Roche Diagnostics
• Abbott
• QIAGEN
• BD
• F. Hoffmann-La Roche Ltd.
• GE Healthcare
• Koninklijke Philips N.V. (Philips)
• Thermo Fisher Scientific
• Inc.
• Illumina
• Inc.
• Siemens Healthcare GmbH
• Hologic
• Inc.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Cancer Diagnosis Market

Which Region Dominates the Cancer Diagnosis Market in 2024?

According to Cognitive Market Research, North America currently dominates the Cancer Diagnosis market, and the region is expected to have significant growth during the projected period. The market is growing as a result of the rising cancer burden in the United States and Canada, as well as medical device makers' growing emphasis on creating innovative cancer-detection diagnostic tools. Additionally, one of the main variables affecting market growth is new releases. For instance, the launch of a clinical study for bladder cancer was announced by Nanostics Inc. in July 2022. The goal of the study is to determine the best markers of the disease for early identification. In order to diagnose bladder cancer, the study will use the Nanostics ClarityDX diagnostic technology to find a minimally invasive liquid biopsy test.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). Due to growing cancer incidence, developing healthcare infrastructure, and growing awareness of early detection, the Asia Pacific region is expected to propel growth in the cancer diagnosis market. In nations like China, India, and Japan, economic growth and rising healthcare spending are making it possible for more people to have access to sophisticated diagnostic tools. The need for biomarker testing, imaging, and molecular diagnostics is increasing as a result of government programs and public health campaigns that support cancer screening. Furthermore, the region is becoming more accessible, especially in isolated places, thanks to the use of point-of-care diagnostics and telemedicine. Asia Pacific is positioned as a major force behind innovation and expansion in the global cancer diagnostics market because of these characteristics.

The current report Scope analyzes Cancer Diagnosis Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Cancer Diagnosis

According to Cognitive Market Research, the global Cancer Diagnosis market size was estimated at USD 109614.5 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 43845.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Cancer Diagnosis market with a market size of USD 34594.34 million in 2024 and is projected to grow at a CAGR of 4.5% during the forecast period. In the U.S., new diagnostic technology development is aided by significant investments made in R&D by research organizations and pharmaceutical businesses.
• The Canadian Cancer Diagnosis market had a market share of USD 5261.50 million in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period. In Canada, because cancer is more common in the aging population, there is a greater need for diagnostic services.
• The Mexico Cancer Diagnosis market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD 3989.97 million in 2024.

Europe Cancer Diagnosis

According to Cognitive Market Research, the global Cancer Diagnosis market size was estimated at USD 109614.5 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 32884.35 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.0% from 2024 to 2031.

• The United Kingdom Cancer Diagnosis market had a market share of USD 5524.57 million in 2024 and is projected to grow at a CAGR of 5.8% during the forecast period. In the UK, the National Health Service (NHS) has put policies into place to enhance cancer treatment and early diagnosis.
• The France Cancer Diagnosis market is projected to witness growth at a CAGR of 4.2% during the forecast period, with a market size of USD 3025.36 million in 2024.
• According to Cognitive Market Research, the German Cancer Diagnosis market size was valued at USD 6511.10 million in 2024 and is projected to grow at a CAGR of 5.2% during the forecast period. Germany's effective healthcare system provides comprehensive cancer care and cutting-edge diagnostic tools.
• The Italy Cancer Diagnosis market is projected to witness growth at a CAGR of 4.4% during the forecast period, with a market size of USD 2828.05 million in 2024.
• The Russia Cancer Diagnosis market is projected to witness growth at a CAGR of 4.0% during the forecast period, with a market size of USD 5097.07 million in 2024.
• The Spain Cancer Diagnosis market is projected to witness growth at a CAGR of 4.1% during the forecast period with a market size of USD 2696.52 million in 2024
• The Luxembourg Cancer Diagnosis market is projected to witness growth at a CAGR of 5.1% during the forecast period, with a market size of USD 1019.41 million in 2024.
• The Portugal Cancer Diagnosis market is projected to witness growth at a CAGR of 4.8% during the forecast period, with a market size of USD 690.57 million in 2024.
• The Greece Cancer Diagnosis market is projected to witness growth at a CAGR of 5.3% during the forecast period, with a market size of USD 394.61 million in 2024.
• The Rest of Europe's Cancer Diagnosis market is projected to witness growth at a CAGR of 3.7% during the forecast period, with a market size of USD 5097.07 million in 2024.

Asia Pacific Cancer Diagnosis

According to Cognitive Market Research, the global Cancer Diagnosis market size was estimated at USD 109614.5 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 25211.34 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.

• According to Cognitive Market Research, the China Cancer Diagnosis market size was valued at USD 11345.10 million in 2024 and is projected to grow at a CAGR of 8.0% during the forecast period. Cancer Diagnosis has surged in China due to the need for diagnostics has increased due to the growth in cancer cases brought on by rapid urbanization and lifestyle changes.
• The Japan Cancer Diagnosis market is projected to witness growth at a CAGR of 7.0% during the forecast period, with a market size of USD 3479.16 million in 2024.
• The India Cancer Diagnosis market had a market share of USD 3025.36 million in 2024 and is projected to grow at a CAGR of 10.3% during the forecast period. India has a high cancer rate, and people are becoming more conscious of the importance of prompt diagnosis.
• The South Korean Cancer Diagnosis market is projected to witness growth at a CAGR of 7.6% during the forecast period, with a market size of USD 2521.13 million in 2024.
• The Australian Cancer Diagnosis market is projected to witness growth at a CAGR of 8.2% during the forecast period, with a market size of USD 1310.99 million in 2024.
• The South East Asia Cancer Diagnosis market is projected to witness growth at a CAGR of 9.5% during the forecast period, with a market size of USD 1739.58 million in 2024.
• The Rest of Asia Pacific Cancer Diagnosis market is projected to witness growth at a CAGR of 8.3% during the forecast period, with a market size of USD 1790.00 million in 2024.

South America Cancer Diagnosis

According to Cognitive Market Research, the global Cancer Diagnosis market size was estimated at USD 109614.5 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 5480.73 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Cancer Diagnosis market size was valued at USD 2345.75 million in 2024 and is projected to grow at a CAGR of 6.5% during the forecast period. Cancer Diagnosis flourished in Brazil due to innovations in cancer diagnostic technology are the result of collaborations between public and private organizations.
• Argentina's Cancer Diagnosis market had a market share of USD 920.76 million in 2024 and is projected to grow at a CAGR of 6.8% during the forecast period. In Argentina, cancer diagnostics and screenings are encouraged by an increasing focus on preventative healthcare interventions.
• Colombia's Cancer Diagnosis market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 487.78 million in 2024.
• Peru's Cancer Diagnosis market is projected to witness growth at a CAGR of 6.1% during the forecast period, with a market size of USD 449.42 million in 2024.
• Chile's Cancer Diagnosis market is projected to witness growth at a CAGR of 6.2% during the forecast period, with a market size of USD 394.61 million in 2024.
• The Rest of Latin America's Cancer Diagnosis market is projected to witness growth at a CAGR of 5.0% during the forecast period, with a market size of USD 882.40 million in 2024.

Middle East and Africa Cancer Diagnosis

According to Cognitive Market Research, the global Cancer Diagnosis market size was estimated at USD 109614.5 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 2192.29 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031..

• The GCC Countries Cancer Diagnosis market is projected to witness growth at a CAGR of 7.0% during the forecast period, with a market size of USD 938.30 million in 2024. Cancer Diagnosis sales flourish in GCC countries due to the demand for diagnostic services being increased by increased public awareness of cancer and screening initiatives.
• The Egypt Cancer Diagnosis market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 230.19 million in 2024.
• The South African Cancer Diagnosis market is projected to witness growth at a CAGR of 7.2% during the forecast period, with a market size of USD 346.38 million in 2024. Cancer Diagnosis sales flourished in South Africa due to growing demand for non-invasive diagnostic tests.
• The Turkey Cancer Diagnosis market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 188.54 million in 2024.
• The Nigeria Cancer Diagnosis market is projected to witness growth at a CAGR of 5.3% during the forecast period, with a market size of USD 230.19 million in 2024.
• The Rest of the MEA Cancer Diagnosis market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD 258.69 million in 2024.

Cancer Diagnosis Market Analysis

How are Segments Performing in the Global Cancer Diagnosis Market?

Cancer Diagnosis Market Type Segment Analysis

According to Cognitive Market Research, consumables are likely to dominate the Cancer Diagnosis Market over the forecast period. The market for consumables in the cancer diagnosis sector is expanding as a result of the growing demand for precise, high-throughput diagnostic techniques. In order to perform imaging, molecular diagnostics, and biomarker testing and enable accurate and efficient cancer detection, consumables such as reagents, test kits, and probes are necessary. Hospitals, diagnostic labs, and research facilities are experiencing an increase in demand for consumables as the number of diagnostic tests rises in tandem with the prevalence of cancer. Furthermore, the trend toward individualized treatment and regular non-invasive test monitoring increases demand for consumables, sustaining steady market expansion in this area.

Instruments are the fastest-growing segment in the Cancer Diagnosis Market. The market for instruments for cancer diagnosis is expanding due to developments in genome sequencing, molecular diagnostics, and imaging technologies. For precise and prompt therapies, key tools including next-generation sequencing (NGS) equipment, MRI, CT, and PET scanners, are necessary for accurate cancer identification and staging. Hospitals, diagnostic labs, and research organizations are investing more in high-performance diagnostic tools as healthcare practitioners seek to enhance early diagnosis and individualized treatment. Diagnostic capabilities are further improved by the move toward sophisticated, automated, and AI-integrated devices, which supports steady expansion in this market niche.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Cancer Diagnosis Industry. Request a Free Sample PDF!

Cancer Diagnosis Market Application Segment Analysis

According to Cognitive Market Research, the breast cancer segment holds the largest share of the market. The rising incidence of breast cancer and the significance of early detection in enhancing results are driving the market for cancer diagnosis. For the early detection of breast cancer, screening methods such as mammography, ultrasound, MRI, and molecular diagnostics are crucial. The need for diagnostic instruments is further increased by rising awareness and government programs encouraging routine breast cancer screening. Personalized approaches to diagnosis and therapy are becoming possible due to improvements in detection accuracy brought about by advancements in imaging technologies, genetic testing, and biomarker analysis. One of the main factors propelling market expansion and innovation is the emphasis on breast cancer diagnosis.

In the Cancer Diagnosis Market, lung cancer has been expanding at a rapid pace. Lung cancer applications are essential in the cancer diagnosis industry because of the high death rate linked to late-stage detection. CT scans, PET scans, molecular testing, and biomarker analysis are important diagnostic techniques that allow for precise and timely detection, which is necessary for successful therapy. The need for these diagnostic instruments is being driven by the increased prevalence of lung cancer, particularly as a result of smoking and environmental factors. The market for this sector is expanding as a result of public health campaigns encouraging early screening and innovations like liquid biopsies and AI-based imaging that are increasing diagnostic sensitivity and specificity.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Cancer Diagnosis Technology Outlook: Segment Analysis

Cancer Diagnosis Market Technology Segment Analysis

According to Cognitive Market Research, the IVD testing segment is expected to dominate the market. In Vitro Diagnostics (IVD) testing technology is becoming more and more important in the cancer diagnosis industry because of its involvement in accurate and early cancer detection. Through the use of genetic testing, immunoassays, and molecular diagnostics, IVD makes it possible to identify cancer biomarkers in tissue, blood, and other materials. IVD demand is rising sharply due to the trend toward personalized medicine, where focused treatments necessitate in-depth genetic knowledge. Liquid biopsies are one non-invasive method that promotes growth. IVD's accuracy, ease of use, and expanding integration with AI for data analysis serve to further solidify its crucial role in contemporary cancer diagnosis.

In the Cancer Diagnosis Market, Imaging has been expanding at a rapid pace. Imaging technology, which offers non-invasive techniques for cancer detection, staging, and monitoring, is a key component of the cancer diagnosis market. Important imaging modalities that provide comprehensive tumor visualization and aid in therapy decision-making include MRI, CT, PET, and ultrasound. High-resolution capabilities and AI-enhanced image processing are two examples of imaging technology advancements that are increasing the precision and effectiveness of diagnosis. Adoption of advanced imaging systems is being fueled by growing healthcare infrastructure investments and awareness of early cancer detection, making this technology a key component of the market expansion for cancer diagnosis.

• IVD Testing
• Biopsy Technique
• Imaging

Cancer Diagnosis End User Outlook: Segment Analysis

Cancer Diagnosis Market End User Segment Analysis

According to Cognitive Market Research, the hospital segment holds the largest share of the market. In the market for cancer diagnosis, hospitals are essential because they are the main end users of cutting-edge diagnostic tools. In order to screen for, diagnose, and stage cancer, hospitals are essential because they have imaging systems, molecular testing, and biopsy capabilities. The necessity for comprehensive diagnostic solutions, the rise in cancer cases, and the developments in precision medicine are the main drivers of the demand for precise, high-throughput diagnostic technologies in hospitals. Growth in this market is also promoted by government programs and financing that assist early cancer detection programs for hospitals. Their incorporation of cutting-edge diagnostic technologies enhances hospitals' ability to improve patient outcomes.

In the Cancer Diagnosis Market, diagnostic laboratories have been expanding at a rapid pace. In the market for cancer diagnosis, diagnostic labs are crucial end users because they offer specialized services for precise cancer monitoring and detection. For sample analysis and cancer biomarker identification, these labs employ cutting-edge technologies like molecular diagnostics, immunohistochemistry, and next-generation sequencing. Diagnostic labs are seeing a surge in testing volumes due to the rising incidence of cancer and the need for early detection. Developments also improve the accuracy and efficiency of laboratories in automation and AI integration. As essential components of the diagnostic process, laboratories play a major role in enhancing patient outcomes and enabling individualized oncology treatment plans.

• Hospitals
• Diagnostic Laboratories

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion